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rDeB: the clinical perspective
Epidermolysis bullosa (EB), a group 
of heritable blistering disorders, is 
caused by mutations in as many as 14 
distinct genes (Fine et al., 2008). The 
clinical spectrum of EB is highly vari-
able, reflecting the level of expres-
sion of these genes within the skin, 
the types and combinations of muta-
tions, and their consequences at mRNA 
and protein levels. These mutations, 
when superimposed on the individual 
patient’s genetic background and expo-
sure to external trauma, explain the tre-
mendous variability in the phenotype 
of this group of disorders.
One distinct subtype of EB, the 
recessive dystrophic variant (RDEB), 
is caused by mutations in the type VII 
collagen gene (COL7A1). The types 
of mutations encountered in COL7A1 
include missense and splice-site muta-
tions, small insertions or deletions that 
result in frame shift, and nonsense 
mutations resulting in premature ter-
mination codons (Varki et al., 2007). 
Again, a spectrum of severity is encoun-
tered in RDEB, which is reflected by 
immunofluorescence findings that can 
reveal either complete absence of type 
VII collagen in the most severe cases or 
attenuated expression in milder forms. 
The immunofluorescence findings can 
also be correlated with the ultrastruc-
tural appearances of anchoring fibrils, 
attachment complexes that are made 
predominantly, if not exclusively, of 
type VII collagen (Chung and Uitto, 
2010) (Figure 1). In the most severe 
cases, no anchoring fibrils are present, 
whereas in milder forms either reduced 
numbers or morphologically altered 
anchoring fibrils may be found. No spe-
cific treatment is currently available for 
this group of devastating diseases.
Development of molecular therapies
With increased understanding of the 
molecular genetics of EB, signifi-
cant progress has been made recently 
toward the development of molecu-
lar approaches at a preclinical level, 
primarily using animal models as a plat-
form (Bruckner-Tuderman et al., 2010; 
Uitto et al., 2010). These approaches 
include development of gene therapy, 
protein replacement, and cell-based 
approaches. Particularly intriguing is 
the progress made in cell-based thera-
pies, which have utilized dermal fibro-
blasts, stem cells, or bone marrow–
derived cells.
The utility of fibroblasts was sug-
gested previously by demonstrations 
that intravenously injected, molecu-
larly engineered RDEB fibroblasts over-
expressing human type VII collagen 
can home to murine skin and deliver 
type VII collagen at the wound site 
(Woodley et al., 2007). This protein was 
then incorporated into the basement 
membrane zone of the skin and formed 
anchoring fibrils. Similarly, studies 
in mice have shown that intradermal 
injections of normal human fibroblasts 
can generate new human type VII col-
lagen and anchoring fibrils at the der-
mal–epidermal junction (Ortiz-Urda et 
al., 2003). Based on these and related 
observations, Wong et al. (2008) gave 
single intradermal injections of allo-
geneic fibroblasts to five subjects with 
RDEB. Increased type VII collagen 
expression at the dermal–epidermal 
junction was noted at 2 weeks and 3 
months following injection, accom-
panied by an increased number of 
anchoring fibrils, although they did not 
have normal morphology. Interestingly, 
it was noted that the increase in type 
VII collagen expression was observed 
primarily in the skin of those individu-
als who showed significant expression 
at baseline, whereas two subjects with 
essentially negative baseline expres-
sion, reflecting the presence of prema-
ture termination codons in COL7A1, 
showed little, if any, increase. At the 
same time, tracking for the presence 
of injected fibroblasts in the skin uti-
lizing Y chromosome–specific probes 
suggested the complete absence of 
allogeneic fibroblasts at 2 weeks after 
intradermal injection. Collectively, 
these observations suggested that the 
major effect of allogeneic fibroblast 
injection is to increase the recipient’s 
own COL7A1 mRNA levels, leading to 
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greater deposition of mutant type VII 
collagen at the basement membrane 
zone. This apparently then results in the 
formation of additional, morphologi-
cally altered, anchoring fibrils that may 
be partially functional and still capable 
of increasing adhesion at the dermal–
epidermal junction (Figure 1).
In this issue, the same group now 
reports on the continuation, for a lon-
ger observation period, of their stud-
ies in one patient from the original 
study (Nagy et al., 2011). This patient 
was selected because the previous 
study reported a positive response 
to fibroblast injection. This patient is 
compound heterozygous for a non-
sense mutation and a splice-site muta-
tion (p.R682X/IVS87+4A→G) in the 
COL7A1 gene; the latter mutation is 
apparently “leaky” and allows expres-
sion of both mutant and normal type 
VII collagen polypeptides. Intradermal 
administration of allogeneic fibroblasts 
increased the type VII collagen pro-
tein levels at the basement membrane 
zone by about 1.5-fold; these remained 
elevated over baseline for about 9 
months after one injection. The authors 
then used gene expression profiling 
to show that, among other factors, the 
expression of heparin binding–EGF-like 
growth factor (HB-EGF) was increased 
after administration of the cells, and 
they hypothesized that this molecule 
may be a key factor stimulating the 
patient’s own keratinocytes to increase 
synthesis of mutant, but partially func-
tional, type VII collagen (Figure 1). The 
study also showed that recombinant 
HB-EGF protein can increase COL7A1 
gene expression in normal or RDEB 
keratinocytes and fibroblasts and that 
this may provide an explanation for 
how allogeneic fibroblasts improve 
skin function in RDEB. This hypothesis 
is currently being tested by expansion 
of these clinical trials to a larger cohort 
of patients with RDEB, with diverse 
genotypes and varied phenotypic pre-
sentations (McGrath et al., personal 
communication). Moreover, assessment 
of the potential benefits of allogeneic 
fibroblasts in chronic wounds, a major 
burden on quality of life in RDEB, 
should also be examined. It should be 
noted, however, that this approach may 
benefit only a subset of patients with 
RDEB (i.e., those who show baseline 
expression of type VII collagen).
Bone marrow transplantation therapy
The observations reported by Nagy 
et al. (2011) may have mechanis-
tic implications for interpreting 
reports on improvement of RDEB 
patients subjected to bone marrow 
transplantation. Specifically, Wagner 
et al. (2010) reported that allogeneic 
bone marrow transplantation resulted 
in increased type VII collagen deposi-
tion in the skin of patients with RDEB. 
Seven children with RDEB were treated 
with immunomyeloablative chemo-
therapy followed by allogeneic stem 
cell transplantation. One of the chil-
dren died from complications of the 
myeloablative preparation before graft-
ing. The six remaining children were 
reported to show substantial improve-
ment in their clinical presentations, 
including one who did not show evi-
dence of type VII collagen expression 
either before or after (60 and 102 days) 
transplantation. Furthermore, although 
increased deposition of type VII colla-
gen at the dermal–epidermal junction 
was reported in five of the six recipi-
ents, there was no normalization of the 
anchoring fibrils. Finally, a substantial 
proportion of cells of donor origin was 
found in the recipients’ skin, but there 
was no evidence that the bone mar-
row–derived cells were the source of 
the increased type VII collagen.
In the context of the observations 
reported by Nagy et al. (2011), it is 
possible that bone marrow transplanta-
tion increases type VII collagen expres-
sion in patients’ skin through immune 
mechanisms caused by the transplanta-
tion procedure itself and that it is not 
synthesized by the allogeneic bone 
marrow–derived cells. This observation 
Figure 1. Schematic representation of the dermal–epidermal junction. (a) Normal skin; (b) blister 
formation in a patient with recessive dystrophic epidermolysis bullosa (RDEB); and (c) postulated 
mechanism by which fibroblast therapy may ameliorate the blistering tendency. (a) In normal skin, 
keratinocytes synthesize type VII collagen molecules (red), which assemble into anchoring fibrils. 
These fibrils entrap the interstitial collagen fibers in the dermis, securing the stable association at 
the dermal–epidermal junction. (b) In some patients with RDEB, there are only a few rudimentary 
anchoring fibrils, allowing formation of blisters below the lamina densa as a result of minor 
trauma. (c) Allogeneic fibroblasts injected directly into dermis elicit an immune reaction that leads 
to synthesis of heparin binding–EGF-like growth factor (HB-EGF), which upregulates the synthesis 
and assembly of the patient’s own mutated type VII collagen. The increase in the rudimentary 
anchoring fibrils, which are partially functional, stabilizes the association of epidermis to the 
underlying dermis and ameliorates the blistering tendency.











•  Direct injection of allogeneic fibroblasts to the dermis can ameliorate 
the blistering tendency in patients with RDEB.
•  Identification of HB-EGF as a key molecule upregulating type 
VII collagen gene expression may provide a safe, selective, and 
mechanistically targeted modality for treatment of patients with RDEB.
•  Further refinement of cell-based therapies may complement the 
ongoing studies on gene therapy and protein replacement toward 
development of molecular therapies for EB.
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may question the value of this approach, 
which carries significant morbidity and 
possible mortality. In fact, in addition 
to the one patient who died of compli-
cations from the myeloablation before 
transplantation, another patient died at 
day 183 from the consequence of graft 
rejection and infection. Finally, one of 
the patients who did not have any evi-
dence of type VII collagen either before 
or after transplantation showed clinical 
improvement that could be attributed, 
at least in part, to improved care dur-
ing extended hospitalization or other 
currently unrecognized factors. Thus, 
alternative approaches, including less 
aggressive nonmyeloablative prepa-
ration of the recipient for bone mar-
row transfer, could be tested (Kiuru et 
al., 2010). Alternatively, utilization of 
patients’ own cells through generation 
of induced pluripotent stem cells should 
be considered (Tolar et al., 2011; Uitto, 
2011). Finally, direct administration of 
molecules, such as HB-EGF, that are 
capable of upregulating type VII col-
lagen gene expression might provide a 
safer, more selective, and mechanisti-
cally targeted approach to treat a subset 
of patients with RDEB.
clinical prospects of cell-based therapies 
for eB
As indicated above, some forms of 
EB, such as RDEB, can be severe, with 
devastating complications, including 
chronic nonhealing ulcers and devel-
opment of highly aggressive squamous 
cell carcinomas, which lead to the 
early demise of affected individuals. 
No specific or effective treatment is 
currently available beyond protection 
from trauma, controlling infection, 
and meticulous wound care. In this 
context, development of new treat-
ment modalities, such as cell-based 
molecular therapies, should be wel-
comed. Nagy et al. (2011) provide sig-
nificant and novel information that can 
be applied to developing cell-based 
therapies for this currently intractable 
group of disorders. Additional studies 
of HB-EGF expression in other RDEB 
patients treated with cell therapies, 
including those undergoing bone 
marrow transplantation, as well as 
mouse studies to explore the effects of 
recombinant HB-EGF in vivo, are now 
warranted.
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